Sign in

You're signed outSign in or to get full access.

Eric Casaburi

Director at OneMedNet
Board

About Eric Casaburi

Eric Casaburi, age 51, is a Class I director of OneMedNet, serving since November 2023 with his term expiring at the 2027 annual meeting; the Board has determined he is independent under Nasdaq and SEC rules . He is an experienced entrepreneur who founded and scaled RetroFitness to approximately $150 million in annual sales, and has led multiple franchise and consumer brands with successful investor exits . Since 2021, he has been founder and CEO of Serotonin Enterprises LLC (anti-aging health optimization), and since 2019 he has chaired TIGER 21 Orlando, alongside operating Longevity Brands (since 2020) and CEVD Holdings (since 2016) .

Past Roles

OrganizationRoleTenureCommittees/Impact
RetroFitnessFounder & CEONot disclosedBuilt national footprint; scaled to ~$150M revenue
Lets YO! YogurtFounder & CEO2012–2015Franchised model; 24 restaurants opened in year one; exited to PE firm
CEVD HoldingsOwner (commercial real estate investment/management)Since 2016Sales/ops systems development across ventures
Longevity BrandsFounder/OperatorSince 2020Operated wellness/health portfolio
Serotonin Enterprises LLCFounder & CEOSince 2021Anti-aging health optimization franchise; featured in Franchise Times
TIGER 21 OrlandoChairSince 2019Peer learning group focused on wealth management transition

External Roles

OrganizationSectorRoleNotes
Serotonin Enterprises LLCHealth optimizationFounder & CEOFranchise model; broad wellness services
TIGER 21 OrlandoPeer investing networkChairGroup focused on wealth stewardship
Longevity BrandsHealth/wellnessFounder/OperatorPortfolio operations
CEVD HoldingsReal estateOwnerCommercial real estate investment/management

Board Governance

  • Independence: The Board determined Casaburi is independent; ONMD’s Board has a majority of independent directors .
  • Committee assignments: Chair, Nominating & Corporate Governance Committee; not a member of Audit or Compensation .
  • Committee activity: In 2024, Nominating & Corporate Governance met 2 times; Audit met 4; Compensation met 1 .
  • Attendance: In 2024 the Board held 2 meetings, and no director attended fewer than 75% of Board and applicable committee meetings; four directors attended the 2024 annual meeting .
  • Board leadership and risk oversight: Chair is separate from CEO; independent directors meet in executive session each regular Board meeting; committee-level risk oversight includes Audit for cybersecurity/financial reporting, Compensation for compensation risk, and Nominating for independence/conflict oversight .

Fixed Compensation

Component (USD / Units)FY 2024
Annual cash retainer$0
Equity grant (policy)45,000 RSUs per full year of service
Equity grant (fair value recognized)$19,350
Meeting/committee fees$0
Expense reimbursementReasonable out-of-pocket expenses reimbursed (no amounts disclosed)

Performance Compensation

Performance MetricFY 2024 Treatment
Performance-based equity (PSUs)None disclosed for directors
Cash bonuses tied to metricsNone disclosed for directors
Specific targets (revenue, EBITDA, TSR, ESG)Not disclosed for directors

Other Directorships & Interlocks

CompanyExchangeRoleInterlock/Conflict Notes
None disclosedNo current public company directorships disclosed for Casaburi

Expertise & Qualifications

  • Serial founder/operator across franchising, health/wellness, food services, and real estate; history of rapid scaling and investor exits .
  • Developed sales, operations, and marketing systems; diversified recurring revenue models .

Equity Ownership

HolderAs of DateShares Beneficially OwnedPercent of Class
Eric CasaburiOct 23, 202565,475<1%
  • Methodology includes RSUs vesting within 60 days in beneficial ownership calculations generally; no vested/unvested breakdown provided for Casaburi .
  • Hedging/pledging: Insider Trading Policy prohibits hedging and pledging transactions for directors and officers .

Governance Assessment

  • Positive indicators:
    • Independent director; majority-independent Board .
    • Chair of Nominating & Corporate Governance, aligning with oversight of board effectiveness and conflicts .
    • Director compensation structure emphasizes equity (RSUs) with no cash retainer, aligning incentives with shareholder value .
    • Executive sessions of independent directors and clear committee risk oversight .
    • No related-person transactions disclosed involving Casaburi in 2023–2025 review .
  • Watch items / red flags to monitor:
    • Low direct ownership (<1%); while typical for small-cap boards, alignment depends on ongoing equity grants and holding practices .
    • Director equity awards appear service-based RSUs with no disclosed performance metrics (PSUs/targets), which may reduce pay-for-performance rigor for directors .
    • Board/committee attendance disclosed in aggregate; individual attendance percentages not detailed (company notes no director below 75%) .

No evidence of conflicts, related-party exposure, pledging, or hedging by Casaburi was disclosed; continued monitoring of any business dealings between ONMD and Casaburi-affiliated entities (Serotonin, Longevity Brands, CEVD Holdings) is prudent given sector adjacency, though none are reported .